Abstract:Background: RAB42 (Ras-related protein 42) is a new small GTPase that controls the vesicular trafficking from endosomes to trans-Golgi network in mammalian cells. However, the role of RAB42 in multiple cancers, especially in liver hepatocellular carcinoma (LIHC), has not been well investigated. Methods: A variety of cancer-related databases and online tools, including TCGA, GTEx, TARGET, QUANTISEQ, EPIC, RNAactDrug, CTR-DB, TIMER algorithms and Sangerbox, were applied to explore the correlation of RAB42 expression with prognosis, immune microenvironment, immune regulatory network, RNA modification, pathway activation and drug sensitivity in pan-cancer. The prognostic, immunomodulatory and tumor-promoting effects of RAB42 were verified in various malignancies and determined by a series of in vitro cellular experiments. Results: RAB42 is significantly overexpressed in most cancers with advanced pathological stages. Its overexpression is correlated with poor survival in pan-cancer. RAB42 overexpression has a high diagnostic accuracy of various cancers (AUC > 0.80). RAB42 overexpression not only correlates with distinct stromal immune infiltration and level of immune checkpoint molecules, but also associates with weak immune cell infiltration, immunomodulatory genes expression, and immunotherapeutic response to immune checkpoint inhibitors (ICIs). Additionally, RAB42 overexpression correlates with enhanced expression of m6A RNA methylation-related genes (MRGs) and its interactors. Moreover, overexpression of RAB42 serves as a drug-resistant marker to certain chemotherapies and acts as a potential biomarker for LIHC. Notably, RAB42 overexpression or activation promotes the cellular proliferation, migration and invasion of LIHC. Conclusion: Overexpressed RAB42 serves as a potential prognostic biomarker and therapeutic target in pan-cancer, especially in LIHC.

Function and regulation of Rab GTPases in cancers

Rab3B Proteins: Cellular Functions, Regulatory Mechanisms, and Potential as a Cancer Therapy Target

High expression of small GTPase Rab3D promotes cancer progression and metastasis

Role of Rab GTPases in Hepatocellular Carcinoma

The Emerging Role of Rab5 in Membrane Receptor Trafficking and Signaling Pathways

Rab5a suppresses autophagy to promote drug resistance in cancer cells

Mechanisms of Rho GTPases in regulating tumor proliferation, migration and invasion

The role of Rab proteins in vesicular membrane trafficking and cell signalling

The Regulation of Rab GTPases by Phosphorylation

RAB42 overexpression correlates with poor prognosis, immune cell infiltration and chemoresistance

Ran GTPase: A Key Player in Tumor Progression and Metastasis

Regulation of autophagy by Rab27B in colorectal cancer

Role of Rab GTPases and their interacting proteins in mediating metabolic signalling and regulation

Autophagy Regulators As Potential Cancer Therapeutic Agents: A Review

Regulation of RAB22A by mir-193b inhibits breast cancer growth and metastasis mediated by exosomes

Rab8A promotes breast cancer progression by increasing surface expression of Tropomyosin-related kinase B

A Rab-bit hole: Rab40 GTPases as new regulators of the actin cytoskeleton and cell migration

Regulation of autophagy in tumor cells and application of targeting autophagy in cancer

Targeting TYK2 alleviates Rab27A-induced malignant progression of non-small cell lung cancer via disrupting IFNα-TYK2-STAT-HSPA5 axis

Rho GTPases in cancer: friend or foe?

Molecular basis and current insights of atypical Rho small GTPase in cancer